: TScan Therapeutics stock soars after Amgen collaboration on Crohn’s disease treatment that could bring in more than $500 million


Shares of TScan Therapeutics Inc. TCRX powered up 43.1% in premarket trading Tuesday, after the biopharmaceutical company announced a collaboration with Amgen Inc. AMGN to treat Crohn’s disease that could be worth more than $500 million to TScan. Amgen shares slipped 0.1% ahead of the open. Under terms of the collaboration, TScan will receive a $30 million upfront payment, and will be eligible to receive more than $500 million in clinical, regulatory and commercial milestone and royalty payments. The multi-year collaboration will use TScan’s TargetScan to identify antigens recognized by T cells in patients with Crohn’s…

This article was originally published by Marketwatch.com. Read the original article here.

Previous article: U.S. could run out of cash as soon as early June, think tank says
Next articleNo debt-limit breakthrough forecast as Biden hosts party leaders at White House


Please enter your comment!
Please enter your name here